Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CAO Sells $21,421.40 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CAO James George Chopas sold 715 shares of the stock in a transaction on Friday, January 17th. The stock was sold at an average price of $29.96, for a total transaction of $21,421.40. Following the sale, the chief accounting officer now directly owns 36,643 shares in the company, valued at $1,097,824.28. This trade represents a 1.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

James George Chopas also recently made the following trade(s):

• On Wednesday, January 22nd, James George Chopas sold 1,096 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $30.43, for a total transaction of $33,351.28.
• On Monday, January 13th, James George Chopas sold 783 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $28.70, for a total value of $22,472.10.

Apellis Pharmaceuticals Price Performance

Shares of Apellis Pharmaceuticals stock opened at $30.76 on Friday. Apellis Pharmaceuticals, Inc. has a 52 week low of $24.34 and a 52 week high of $71.90. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. The stock has a market cap of $3.83 billion, a PE ratio of -15.15 and a beta of 0.94. The company’s 50-day moving average price is $31.95 and its two-hundred day moving average price is $33.25.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its earnings results on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). The business had revenue of $196.83 million during the quarter, compared to the consensus estimate of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm’s revenue for the quarter was up 78.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.17) earnings per share. As a group, sell-side analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.71 EPS for the current fiscal year.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Large investors have recently modified their holdings of the stock. KBC Group NV raised its position in shares of Apellis Pharmaceuticals by 3,862.3% during the fourth quarter. KBC Group NV now owns 104,287 shares of the company’s stock worth $3,328,000 after purchasing an additional 101,655 shares during the period. Merit Financial Group LLC acquired a new stake in Apellis Pharmaceuticals during the 4th quarter worth about $254,000. Hennion & Walsh Asset Management Inc. lifted its stake in Apellis Pharmaceuticals by 135.6% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 29,740 shares of the company’s stock valued at $949,000 after buying an additional 17,115 shares in the last quarter. Eastern Bank boosted its holdings in shares of Apellis Pharmaceuticals by 87.0% in the fourth quarter. Eastern Bank now owns 21,500 shares of the company’s stock worth $686,000 after buying an additional 10,000 shares during the period. Finally, JPMorgan Chase & Co. increased its position in shares of Apellis Pharmaceuticals by 23.3% in the third quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock worth $112,036,000 after acquiring an additional 735,160 shares in the last quarter. 96.29% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on APLS. HC Wainwright reissued a “buy” rating and issued a $57.00 price target on shares of Apellis Pharmaceuticals in a report on Tuesday, January 14th. Oppenheimer reduced their price target on shares of Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. Wells Fargo & Company dropped their price objective on shares of Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 6th. Mizuho reduced their target price on shares of Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating for the company in a research note on Thursday, October 24th. Finally, Needham & Company LLC dropped their price target on shares of Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Eight equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Apellis Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $46.71.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).